Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2000
08/01/2000US6096729 Use of NK-1 receptor antagonists for treating amnestic disorders
08/01/2000US6096713 Administering to patient a linear or cyclized derivative of glutamic acid-tryptophan dipeptide or a low molecular weight oligo- or polypeptide based upon the dipeptide unit
08/01/2000US6096517 Human kidney sodium bicarbonate transporter (HNBC1A) polynucleotides
08/01/2000US6096516 cDNAs encoding murine antibody against human plasma apolipoprotein B-100
08/01/2000US6096513 Amino acid sequences; for screening agonists and antagonists; for analgesics
08/01/2000US6096359 Polyphenol fractions of tea, the use thereof and formulations containing them
08/01/2000US6096347 Healing of damaged heart tissue; grafting with submucosal tissue
08/01/2000CA2209925C 5,6-diaryl-5,6,7,8-tetrahydronaphthalenes and their analogs as estrogen agonists/antagonists
08/01/2000CA2189250C Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
08/01/2000CA2158058C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
08/01/2000CA2151618C Derivatives of benzoylecgonine, ecgonine and ecgonidine as medicines
08/01/2000CA2121571C Substituted phenoxy isobutyric acids and esters
08/01/2000CA2015034C Piperazine derivatives
08/01/2000CA1341064C Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfunctions
07/2000
07/29/2000CA2260397A1 Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
07/27/2000WO2000043553A1 Identifying, monitoring, and treating women for breast precancer or cancer
07/27/2000WO2000043524A1 Polypeptides derived from jnk3
07/27/2000WO2000043495A2 33 human secreted proteins
07/27/2000WO2000043415A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000WO2000043414A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
07/27/2000WO2000043413A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000WO2000043404A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
07/27/2000WO2000043398A2 Tricyclic benzodiazepines as vasopressin receptor antagonists
07/27/2000WO2000043392A2 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
07/27/2000WO2000043391A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application
07/27/2000WO2000043378A1 New morpholinobenzamide salts
07/27/2000WO2000043371A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000WO2000043370A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
07/27/2000WO2000043354A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000WO2000043058A1 Method of enhancing needleless transdermal powdered drug delivery
07/27/2000WO2000043042A1 Parenteral metolazone formulations
07/27/2000WO2000043039A1 Vaccine-mediated treatment of neurological disorders
07/27/2000WO2000043038A1 Methods and devices for delivery of agents to breast milk ducts
07/27/2000WO2000043032A2 Baff, inhibitors thereof and their use in the modulation of b-cell response
07/27/2000WO2000043028A2 Method of treating chronic cardiac disease
07/27/2000WO2000043021A1 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt
07/27/2000WO2000043018A1 Medicinal compositions
07/27/2000WO2000043016A1 DICARBA-closo-DODECABORANE DERIVATIVES
07/27/2000WO2000043011A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use
07/27/2000WO2000042998A1 Multiparticulate bisoprolol formulation
07/27/2000WO2000042989A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
07/27/2000WO2000042864A2 Methods for reducing mortality rates in poultry
07/27/2000WO2000042852A1 Compounds and methods
07/27/2000WO2000042841A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
07/27/2000WO2000028010A3 The genetic determination of genes and its use for the prophylaxis and therapy of diseases
07/27/2000WO2000027832A3 Thiazole derivatives as ppar gamma ligands
07/27/2000WO2000023094A3 Methods of inhibiting platelet activation and recruitment
07/27/2000WO2000017328A3 Fibrils
07/27/2000WO2000011171A3 Human rna-associated proteins
07/27/2000WO2000008202A9 3-methylidenyl-2-indolinone modulators of protein kinase
07/27/2000WO2000002998A9 Methods for implanting cells
07/27/2000WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors
07/27/2000CA2361272A1 33 human secreted proteins
07/27/2000CA2361124A1 Vaccine-mediated treatment of neurological disorders
07/27/2000CA2361123A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
07/27/2000CA2361122A1 Methods and devices for delivery of agents to breast milk ducts
07/27/2000CA2360787A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
07/27/2000CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response
07/27/2000CA2360038A1 Methods for reducing mortality rates in poultry
07/27/2000CA2359709A1 Multiparticulate bisoprolol formulation
07/27/2000CA2359681A1 Method of treating chronic cardiac disease
07/27/2000CA2359572A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use
07/27/2000CA2359114A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359113A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359112A1 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359105A1 New morpholinobenzamide salts
07/27/2000CA2359103A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application
07/27/2000CA2359096A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
07/27/2000CA2358971A1 Identifying, monitoring, and treating women for breast precancer or cancer
07/27/2000CA2358914A1 Polypeptides derived from jnk3
07/27/2000CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery
07/27/2000CA2358474A1 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt
07/27/2000CA2358093A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2357781A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
07/26/2000EP1022272A1 Substituted fused heterocyclic compounds
07/26/2000EP1021553A2 Eukaryotic gene expression cassette and uses thereof
07/26/2000EP1021549A2 SENSE mRNA THERAPY
07/26/2000EP1021546A1 Neutral sphingomyelinase
07/26/2000EP1021444A1 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES
07/26/2000EP1021430A1 Furan nitrone compounds
07/26/2000EP1021413A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
07/26/2000EP1021407A1 Synthesis of clasto-lactacystin beta-lactone and analogs thereof
07/26/2000EP1021199A1 PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
07/26/2000EP1021195A1 Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
07/26/2000EP1021189A1 Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
07/26/2000EP1021188A1 Inhibitors of prenyl-protein transferase
07/26/2000EP1021186A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha
07/26/2000EP1021185A1 Didhydropyrimidines and uses thereof
07/26/2000EP1021182A1 Indeno[1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity
07/26/2000EP1021181A1 Carboxylic acid indole inhibitors of chemokines
07/26/2000EP1021177A1 Compositions and methods for prevention and treatment of vascular degenerative diseases
07/26/2000EP1021175A1 Compounds and methods for therapeutic intervention in preventing diabetic complications
07/26/2000EP0736011B1 Anellated dihydropyridines and their use in the production of pharmaceutical preparations
07/26/2000EP0643583B1 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
07/26/2000CN1261367A Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents
07/26/2000CN1261366A Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
07/26/2000CN1261354A Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
07/26/2000CN1261353A Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
07/26/2000CN1261352A New 'beta'-amino and 'beta'-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor an tagonists
07/26/2000CN1261280A Improved methods for processing activated protein C
1 ... 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 ... 1595